Viktoria Moschetti

1.3k total citations
23 papers, 1.0k citations indexed

About

Viktoria Moschetti is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Molecular Biology. According to data from OpenAlex, Viktoria Moschetti has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 6 papers in Internal Medicine and 4 papers in Molecular Biology. Recurrent topics in Viktoria Moschetti's work include Atrial Fibrillation Management and Outcomes (10 papers), Venous Thromboembolism Diagnosis and Management (6 papers) and Biosimilars and Bioanalytical Methods (4 papers). Viktoria Moschetti is often cited by papers focused on Atrial Fibrillation Management and Outcomes (10 papers), Venous Thromboembolism Diagnosis and Management (6 papers) and Biosimilars and Bioanalytical Methods (4 papers). Viktoria Moschetti collaborates with scholars based in Germany, United States and Canada. Viktoria Moschetti's co-authors include Joachim Stangier, Paul Reilly, Stephan Glund, Michael Schmohl, Benjamin Lang, Stephen H. Norris, Steven Ramael, Joanne van Ryn, Dietmar Ganßer and Jörg Kreuzer and has published in prestigious journals such as The Lancet, Circulation and Blood.

In The Last Decade

Viktoria Moschetti

22 papers receiving 974 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Viktoria Moschetti Germany	15	740	523	100	93	92	23	1.0k
Puneet Mohan United States	16	1.5k 2.0×	651 1.2×	127 1.3×	155 1.7×	160 1.7×	30	1.7k
Alex Pokov United States	11	496 0.7×	153 0.3×	241 2.4×	29 0.3×	56 0.6×	16	595
Karin Hermansson Sweden	10	521 0.7×	431 0.8×	109 1.1×	28 0.3×	93 1.0×	13	726
Chern‐En Chiang Taiwan	20	1.4k 1.9×	225 0.4×	139 1.4×	288 3.1×	189 2.1×	55	1.6k
Benjamin Hafner Italy	6	535 0.7×	134 0.3×	259 2.6×	32 0.3×	105 1.1×	11	885
Irene Savelieva United Kingdom	13	1.5k 2.0×	231 0.4×	100 1.0×	76 0.8×	101 1.1×	15	1.6k
Julie H. Oestreich United States	12	604 0.8×	210 0.4×	315 3.1×	55 0.6×	29 0.3×	29	811
Dan Atar United States	13	417 0.6×	81 0.2×	86 0.9×	32 0.3×	45 0.5×	25	557
Henri Caplain France	12	287 0.4×	244 0.5×	206 2.1×	24 0.3×	14 0.2×	23	619
Jonas Olesen Denmark	4	448 0.6×	139 0.3×	109 1.1×	25 0.3×	77 0.8×	7	658

Countries citing papers authored by Viktoria Moschetti

Since Specialization

Citations

This map shows the geographic impact of Viktoria Moschetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Viktoria Moschetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Viktoria Moschetti more than expected).

Fields of papers citing papers by Viktoria Moschetti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Viktoria Moschetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Viktoria Moschetti. The network helps show where Viktoria Moschetti may publish in the future.

Co-authorship network of co-authors of Viktoria Moschetti

This figure shows the co-authorship network connecting the top 25 collaborators of Viktoria Moschetti. A scholar is included among the top collaborators of Viktoria Moschetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Viktoria Moschetti. Viktoria Moschetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moschetti, Viktoria, et al.. (2024). Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF). Expert Opinion on Biological Therapy. 24(7). 673–679.

Hanauer, Stephen B., et al.. (2021). Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. Gastroenterology & hepatology. 6(10). 816–825. 30 indexed citations

Moschetti, Viktoria, Maria Kim, Michael Sand, et al.. (2018). The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers. European Neuropsychopharmacology. 28(5). 643–655. 10 indexed citations

Ramael, Steven, Renger G. Tiessen, Thijs van Iersel, et al.. (2018). Similar Pharmacokinetics of the Adalimumab (Humira®) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE®-AI and VOLTAIRE®-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials. Rheumatology and Therapy. 5(2). 403–421. 14 indexed citations

Moschetti, Viktoria, Christina Schlecker, Sven Wind, et al.. (2018). Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics. Clinical Drug Investigation. 38(8). 737–750. 26 indexed citations

Rosenbrock, Holger, Michael Desch, Oliver Kleiner, et al.. (2018). Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies. Clinical and Translational Science. 11(6). 616–623. 33 indexed citations

Moschetti, Viktoria, Michael Desch, Karl‐Heinz Liesenfeld, et al.. (2017). Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study. European Journal of Drug Metabolism and Pharmacokinetics. 43(2). 239–249. 28 indexed citations

Norris, Stephen H., Steven Ramael, Ippei Ikushima, et al.. (2017). Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. British Journal of Clinical Pharmacology. 83(8). 1815–1825. 9 indexed citations

Moschetti, Viktoria, C. Dansirikul, Lien Gheyle, et al.. (2017). A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers. Human Psychopharmacology Clinical and Experimental. 32(1). 24 indexed citations

10.

Schmohl, Michael, Stephan Glund, Akiko Harada, et al.. (2016). Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers. Thrombosis and Haemostasis. 117(2). 269–276. 23 indexed citations

11.

Glund, Stephan, Joachim Stangier, Joanne van Ryn, et al.. (2016). Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study. Clinical Pharmacokinetics. 56(1). 41–54. 58 indexed citations

12.

Schmohl, Michael, Dietmar Ganßer, Viktoria Moschetti, & Joachim Stangier. (2015). Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis. Thrombosis Research. 135(3). 532–536. 11 indexed citations

13.

Moschetti, Viktoria, Stephen H. Norris, Joachim Stangier, et al.. (2015). A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thrombosis and Haemostasis. 113(5). 943–951. 183 indexed citations

14.

Glund, Stephan, Joachim Stangier, Michael Schmohl, et al.. (2015). Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. The Lancet. 386(9994). 680–690. 237 indexed citations

15.

Moschetti, Viktoria, et al.. (2015). P1‐295: Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple‐rising doses of bi409306 film‐coated tablets given orally once‐ or twice‐daily for 14 days in young and elderly healthy volunteers. Alzheimer s & Dementia. 11(7S_Part_10). 3 indexed citations

16.

Glund, Stephan, Joachim Stangier, Michael Schmohl, et al.. (2014). Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. Blood. 124(21). 344–344. 59 indexed citations

17.

Ryn, Joanne van, Lien Gheyle, Viktoria Moschetti, et al.. (2014). Abstract 18403: Effect of Dabigatran on the Ability to Generate Fibrin at a Wound site and its Reversal by Idarucizumab, the Antidote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood Loss. Circulation. 130(suppl_2). 15 indexed citations

18.

Huang, Fenglei, Viktoria Moschetti, Benjamin Lang, et al.. (2014). Pharmacokinetics, Safety, and Tolerability of Faldaprevir in Patients with Renal Impairment. Antimicrobial Agents and Chemotherapy. 59(1). 251–257. 4 indexed citations

19.

Glund, Stephan, Joachim Stangier, Michael Schmohl, et al.. (2013). Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers. Circulation. 128. 41 indexed citations

20.

Formella, Stephan, Erol Wiegert, Viktoria Moschetti, et al.. (2013). Effective elimination of dabigatran by haemodialysis. Thrombosis and Haemostasis. 109(4). 596–605. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact